Navigation Links
PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
Date:8/9/2011

BOSTON, Aug. 9, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) today reported financial results for the fourth quarter and fiscal year ended June 30, 2011.  

For the three months ended June 30, 2011 consolidated service revenue increased by 5.2% to $310.5 million compared with $295.3 million in the prior year period.  Excluding the positive impact from foreign exchange movements in the quarter of $12.0 million, revenue increased 1.1%.  Operating income as reported under Generally Accepted Accounting Principles (GAAP) totaled $1.6 million, or 0.5% of consolidated service revenue, in the fourth quarter of Fiscal Year 2011, as compared with $20.1 million, or 6.8% of consolidated service revenue, in the comparable quarter of the prior year.  GAAP operating income declined 92.2% year-over-year.  

The financial results of the June quarter in the current and prior periods each included special items, as detailed in the financial charts within this press release.  Excluding the impact of special items, adjusted operating income in the fourth quarter of Fiscal Year 2011 was $10.5 million, or 3.4% of consolidated service revenue.  Excluding the special items referenced above in the prior year period, adjusted operating income was $28.2 million, or 9.6% of consolidated service revenue, in the fourth quarter of Fiscal Year 2010.  On this adjusted basis, operating income in the current quarter declined 62.8% year-over-year.  The GAAP net loss for the quarter totaled $1.6 million, or a loss of $0.03 per share, compared with GAAP net income of $12.9 million, or $0.22 per diluted share, for the quarter ended June 30, 2010.  On a GAAP basis, the net loss in the current quarter was a decline of 112.2% year-over-year, and the loss per share was a decline of 113.6%.  Adjusted net income in the current and prior periods (which excludes the special items referenced above) was $6.1 million, or $0.10 per diluted share in the quarter ended June 30, 2011, and was $19.1 million, or $0.32 per diluted share in the quarter ended June 30, 2010.  Using adjusted numbers in both periods, adjusted net income in the current quarter declined by 68.2% year-over-year, and adjusted earnings per diluted share declined by 68.8%.

Consolidated service revenue for the fourth quarter of Fiscal Year 2011 was $232.8 million in Clinical Research Services (CRS), $35.2 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $42.5 million in Perceptive Informatics, Inc. (Perceptive).

On a GAAP basis for the full fiscal year ended June 30, 2011, consolidated service revenue was $1,212.1 million versus $1,131.0 million in the prior year, a year-over-year increase of 7.2%.  Excluding the positive impact of foreign exchange of approximately $3.8 million in Fiscal Year 2011, revenue increased 6.8% from the prior year.  For Fiscal Year 2011, GAAP operating income was $81.6 million, or 6.7% of consolidated service revenue, compared with GAAP Fiscal Year 2010 operating income of $83.1 million, or 7.3% of consolidated service revenue.  GAAP operating income declined 1.8% year-over-year.  

Excluding the impact of special items, as detailed in the attached financial tables in both periods, adjusted operating income was $90.1 million, or 7.4% of consolidated service revenue in Fiscal Year 2011, compared with adjusted operating income of $103.5 million, or 9.1% of consolidated service revenue, in Fiscal Year 2010.  On this adjusted basis, operating income in Fiscal Year 2011 declined 12.9% year-over-year.  Net income on a GAAP basis for Fiscal Year 2011 was $48.8 million, or $0.81 per diluted share, compared with GAAP net income of $41.5 million, or $0.71 per diluted share, in Fiscal Year 2010.  On a GAAP basis, net income in the current year increased by 17.4%, and earnings per diluted share increased by 14.1%.  On an adjusted basis, excluding the special items noted in the attached financial charts in both periods, net income for the twelve months ended June 30, 2011 was $56.9 million, or $0.95 per diluted share, compared with $63.5 million, or $1.08 per diluted share, in the comparable prior year twelve-month period.  Using adjusted numbers in both periods, adjusted net income in the current quarter declined by 10.4%, and adjusted earnings per diluted share declined by 12.0%.  

Consolidated service revenue for Fiscal Year 2011 was $922.8 million in CRS, $129.7 million in PCMS, and $159.5 million in Perceptive.

The Company reported a Fiscal Year 2011 ending backlog of $3.44 billion, an increase of 28.5% over the ending backlog reported for Fiscal Year 2010, and an increase of 8% from the third quarter of Fiscal Year 2011.  The reported backlog included gross new business wins in the quarter of $675.1 million, cancellations of $107.2 million, and a negative impact from foreign exchange rates of $1.7 million.  The net book-to-bill ratio was 1.83 for the quarter, and was 1.51 for Fiscal Year 2011 overall.

Mr. Josef H. von Rickenbach, PAREXEL’s Chairman and Chief Executive Officer, stated, “The results of the fourth quarter generally met our expectations, and we were especially pleased with our strong new business results.  We were excited to see an uptick in activity from clients in the small and emerging biopharma segment in the quarter, and we expect to continue to win our fair share in this market segment going forward.  For the Company overall, I believe that the groundwork that we laid in Fiscal Year 2011 has created a solid foundation for our future.  We have been building a Company based on robust processes and systems, which we believe affords us long-term sustainable advantages that enable us to deliver strong returns to our clients and shareholders alike.”

He continued, “Fiscal Year 2011 presented us with many exciting new business opportunities, as many of our clients embraced a new way of working with us.  The year’s new business and backlog results clearly demonstrate that PAREXEL is a partner of choice for many clients.  Our expertise-based, globally integrated, and technology-enabled strategy has been effective.  It has resonated with clients who understand the value that we can create for them.”

With regard to the future outlook for the Company, Mr. von Rickenbach commented, “As we enter into Fiscal Year 2012, our focus is on revenue growth, successfully executing quality projects for clients, and on increasing operating income by further reaping the benefits of our productivity and efficiency initiatives.  We plan to continue making judicious investments by adding to our talent base to meet current and future project needs.  We anticipate that as the year progresses, some of the more mature strategic partnerships will hit their stride.  We also anticipate that we will achieve a restoration of our profitability over the course of the year, as productivity starts to improve and as a variety of initiatives and the previously-announced restructuring bear fruit.”

The Company issued forward-looking guidance for the first quarter of Fiscal Year 2012 (ending September 30, 2011), and for Fiscal Year 2012.  The Company expects to report consolidated service revenue for the first quarter (ending September 30, 2011) in the range of $312 to $322 million, GAAP earnings per diluted share in the range of $0.10 to $0.12, and adjusted earnings per diluted share in the range of $0.16 to $0.18.  For Fiscal Year 2012, consolidated service revenue is expected to be in the range of $1.355 to $1.395 billion, GAAP earnings per diluted share in the range of $0.95 to $1.14, and adjusted earnings per diluted share in the range of $1.05 to $1.24.  (Previously issued guidance for Fiscal Year 2012 was for service revenue of $1.340 to $1.380 billion, GAAP earnings per diluted share of $0.93 - $1.10, and adjusted earnings per diluted share of $1.05 to $1.22 (excluding the impact of restructuring and related charges)).

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures.  The Company believes that presenting the non-GAAP financial measures contained in this press release assists investors and others in gaining a better understanding of its core operating results and future prospects, especially when comparing such results to previous periods or forecasted guidance, because such measures exclude items that are outside of the Company’s normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.  Management uses non-GAAP financial measures, in addition to the measures prepared in accordance with GAAP, as the basis for measuring the Company’s core operating performance and comparing such performance to that of prior periods and to the performance of its competitors for the same reasons stated above.  Such measures are also used by management in its financial and operating decision-making.  Non-GAAP financial measures are not meant to be considered superior to or a substitute for the Company’s results of operations prepared in accordance with GAAP.

A conference call to discuss PAREXEL’s fourth quarter and fiscal year earnings, business, and financial outlook will begin at 10:00 a.m. ET on Wednesday, August 10, 2011 and will be broadcast live over the internet via webcast.  The webcast may be accessed in the “Upcoming Events” portion of the main page of the Investor Relations section of the Company’s website at www.parexel.com.   Users should follow the instructions provided to assure that the necessary audio applications are downloaded and installed.  A replay of this webcast will be archived on the website approximately two hours after the call and will continue to be accessible for approximately one year following the live event.  To participate via telephone, dial +1 (408) 940-3886 and ask to join the PAREXEL quarterly conference call.

Certain trended financial information may be found in the Investor Relations section of the Company’s website under the “Additional Financials” section.  

About PAREXEL International PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,550 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.  For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,”  “targets,” and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $18 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which “Risk Factors” discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.CONTACTS:

James Winschel, Senior Vice President and Chief Financial OfficerJill Baker, Corporate Vice President of Investor Relations+1-781-434-4118PAREXEL International CorporationConsolidated Condensed Statement of OperationsUnauditedThree Months EndedThree Months Ended(in thousands, except per share data)June 30, 2011June 30, 2010 (a)As ReportedAdjustmentsNon-GAAPAs ReportedAdjustmentsNon-GAAPService revenue$
310,524$
-$  310,524$
295,301$
-$  295,301Reimbursement revenue52,63352,63350,65050,650  Total revenue363,157-363,157345,951-345,951Costs and expenses:Direct costs209,870209,870184,770184,770Reimbursable out-of-pocket expenses52,63352,63350,65050,650Selling, general and administrative 72,53572,53571,143(4,250)

(d)

66,893Depreciation15,11115,11112,78412,784Amortization2,5232,5232,6462,646 Other benefit ----Restructuring charge8,924(8,924)

(b)

-3,860(3,860)

(e)

-  Total costs and expenses361,596(8,924)352,672325,853(8,110)317,743Income from operations1,5618,92410,48520,0988,11028,208Other (expense) income(205)1,076

(c)

871(2,860)-(2,860)Income before income taxes1,35610,00011,35617,2388,11025,348Provision for income tax expense2,9272,353

(f)

5,2804,3701,866

(f)

6,236Effective tax rate215.9%46.5%25.4%24.6%Net (loss) income($1,571)$
7,647$
,076$
2,868$
,244$
9,112(Loss) earnings per common share:Basic($0.03)$
.10$
.22$
.33Diluted($0.03)$
.10$
.22$
.32Shares used in computing earnings per common share:Basic58,90258,90258,37158,371Diluted58,90260,34759,63659,636(a) Prior year numbers have been reclassified to conform with the current year presentation.(b) Restructuring charges pursuant to plans previously announced, as well as those implemented, in FY11 include $4.3 million of facility-related costs, $1.5 million in severance costs, and $3.1 million in impairment charges related to exited facilities.(c) Accelerated amortization of financing fees related to debt refinancing.(d) Legal settlement costs related to a small acquisition which was completed several years ago.(e) Restructuring charges pursuant to plans previously announced, as well as those implemented, in FY10 include $0.5 million of facility-related benefits and $4.4 million in severance costs.(f) Tax associated with items (b) - (e).Balance Sheet InformationPreliminaryJune 30,March 31,June 30,201120112010Billed accounts receivable, net

$
341,279$
355,733$
229,932Unbilled accounts receivable, net

308,364279,832248,994Deferred revenue

(332,662)(321,007)(261,080)Net receivables

$
316,981$
314,558$
217,846Cash and marketable securities

$
89,056$
9,424$
7,413Working capital

$
317,298$
251,803$
58,624Total assets

$ 1,429,483$   1,443,834$
,220,710Short-term borrowings

$
5,867$
,787$
32,082Long-term debt

$
240,102$
77,583$
83,707Stockholders' equity

$
566,004$
558,763$
439,555PAREXEL International CorporationConsolidated Condensed Statement of OperationsUnauditedTwelve Months EndedTwelve Months Ended(in thousands, except per share data)June 30, 2011June 30, 2010 (a)As ReportedAdjustmentsNon-GAAPAs ReportedAdjustmentsNon-GAAPService revenue$   1,212,099$1,212,099$   1,131,039$1,131,039Reimbursement revenue210,326210,326204,836204,836  Total revenue1,422,425-1,422,4251,335,8751,335,875Costs and expenses:Direct costs785,834(368)

(b)

785,466718,844

(a)718,844Reimbursable out-of-pocket expenses210,326-210,326204,836204,836Selling, general and administrative 271,049(7)

(b)

271,042253,100

(a)

(4,250)

(c)

248,850Depreciation55,549-55,54949,943(450)

(d)

49,493Amortization9,931-9,93110,37710,377 Other benefit --(1,144)1,144

(e)

-Restructuring (benefit) charge8,106(8,106)

(b)

-16,810(16,810)

(d)

-  Total costs and expenses1,340,795(8,481)1,332,3141,252,766(20,366)1,232,400Income from operations81,6308,48190,11183,10920,366103,475Other expense(22,996)2,242

(f)

(20,754)(19,934)6,572

(f)

(13,362)Income before income taxes58,63410,72369,35763,17526,93890,113Provision for income taxes9,8482,623

(g)

12,47121,6334,972

(g)

26,605Effective tax rate16.8%18.0%34.2%29.5%Net income$
48,786$
8,100$
56,886$
41,542$
21,966$
3,508Earnings per common share:Basic$
.83$
.97$
.72$
.09Diluted$
.81$
.95$
.71$
.08Shares used in computing earnings per common share:Basic58,63458,63458,06258,062Diluted59,87459,87458,75658,756(a) Prior year numbers have been reclassified to conform with the current year presentation.(b) Restructuring charges pursuant to plans previously announced, as well as those implemented, in FY11 include $4.1 million of facility-related costs,  $1.3 million in severance costs, and $3.1 million in impairment charges related to exited facilities.(c) Legal settlement costs related to a small acquisition which was completed several years ago.(d) Restructuring charges pursuant to plans previously announced, as well as those implemented, in FY10 include $0.5 million of accelerated depreciation, $5.2 million of facility-related costs and $11.6 million in severance costs.(e) Release of $1.1 million in certain reserves related to the $15 million wind-down costs and bad debt expense established in Q2 FY09 for a client contract default.(f) Impairment charge on an asset  and accelerated amortization of financing fees related to debt refinancing (FY11) and impairment charges on an investment and an asset (FY10).(g) Tax associated with items (b) - (f).PAREXEL International CorporationSegment InformationUnauditedThree Months EndedThree Months Ended(in thousands)June 30, 2011June 30, 2010 (a)As ReportedAs ReportedClinical Research Services (CRS)Service revenue $
232,818$
225,371% of total service revenue75.0%76.3%Gross profit$
8,021$
79,839Gross margin % of service revenue29.2%35.4%PAREXEL Consulting & Medical Communications  Services (PCMS)Service revenue$
35,244$
31,582% of total service revenue11.3%10.7%Gross profit$
4,407$
2,941Gross margin % of service revenue40.9%41.0%Perceptive Informatics, Inc. (PII)Service revenue$
42,462$
38,348% of total service revenue13.7%13.0%Gross profit$
8,226$
7,751Gross margin % of service revenue42.9%46.3%Total service revenue$
310,524$
295,301Total gross profit$
,654$
,531Gross margin % of service revenue32.4%37.4%Revenue by GeographyThe Americas$
7,576$
23,871Europe, Middle East & Africa146,063134,603Asia/Pacific46,88536,827Total service revenue$
310,524$
295,301Quarterly Supplemental Financial DataTotal revenue$
363,157$
345,951Investigator fees52,07954,590Gross revenue$
415,236$
400,541Days sales outstanding6949Capital expenditures21,42630,436(a) Prior year numbers have been reclassified to conform with the current year presentation.PAREXEL International CorporationSegment InformationUnauditedTwelve Months EndedTwelve Months Ended(in thousands)June 30, 2011June 30, 2010 (a)As ReportedAdjustmentsNon-GAAPAs ReportedClinical Research Services (CRS)Service revenue $
922,827$
922,827$
870,721% of total service revenue76.1%76.1%77.0%Gross profit$
306,150201

(b)

$
306,351$
307,937Gross margin % of service revenue33.2%33.2%35.4%PAREXEL Consulting & Medical Communications  Services (PCMS)Service revenue$
29,728$
29,728$
21,652% of total service revenue10.7%10.7%10.8%Gross profit$
52,04955

(b)

$
52,104$
46,386Gross margin % of service revenue40.1%40.2%38.1%Perceptive Informatics, Inc. (PII)Service revenue$
59,544$
59,544$
38,666% of total service revenue13.2%13.2%12.2%Gross profit$
8,066112

(b)

$
8,178$
57,872Gross margin % of service revenue42.7%42.7%41.7%Total service revenue$   1,212,099$ 1,212,099$   1,131,039Total gross profit$
426,265368$
426,633$
412,195Gross margin % of service revenue35.2%35.2%36.4%Revenue by GeographyThe Americas$
484,657$
484,657$
449,357Europe, Middle East & Africa553,801553,801548,412Asia/Pacific173,641173,641133,270Total service revenue$   1,212,099$ 1,212,099$   1,131,039(a) Prior year numbers have been reclassified to conform with the current year presentation.(b) Severance associated with FY11 restructuring activities.
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2011 Earnings Release and Conference Call
3. PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference
4. PAREXEL Invites Public to Listen to Live Webcast of Its Investor Day June 2, 2011
5. PAREXEL Reports Third Quarter Fiscal Year 2011 Financial Results
6. Key Presentations Announced for Landmark Future of Biosimilars Event Co-Sponsored by DIA and FDLI, Co-Chaired by Merck and PAREXEL
7. PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market
8. PAREXEL Announces Date of Third Quarter Fiscal Year 2011 Earnings Release and Conference Call
9. PAREXEL Experts To Address Best-Practice Strategic Partnership Models To Increase Operating Efficiency, Development Effectiveness at Partnerships in Clinical Trials
10. PAREXEL Experts to Present Advanced Approaches to Accelerate Development, Maximize Product Value at DIA EuroMeeting
11. PAREXEL International to Present at Raymond James Investors Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... Islandia, NY (PRWEB) , ... December 08, 2016 ... ... company, is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture ... published in JMIR Medical Informatics . , Results of the comparative usability ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Center has been recognized for adherence to the highest standards of trauma, ... accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among ...
(Date:12/8/2016)... ... 2016 , ... Vida Health, the digital health platform that pairs ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect ... consumers who are managing chronic conditions or simply want to improve their ...
Breaking Medicine News(10 mins):